Attached files
| file | filename |
|---|---|
| EX-99.1 - Protagenic Therapeutics, Inc.\new | v217234_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 31, 2011
ATRINSIC, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-12555
|
06-1390025
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
469 7th Avenue, 10th Floor, New York, NY 10018
(Address of Principal Executive Offices/Zip Code)
(212) 716-1977
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
|
|
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 2.02.
|
Results of Operations and Financial Condition
|
On March 31, 2011, Atrinsic, Inc. (the “Company”), issued a press release announcing its 2010 fourth quarter and full year financial results, a copy of which is attached hereto as Exhibit 99.1.
The information in this Item 2.02 of the Company’s Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
In addition to historic information, this report, including Exhibit 99.1, contains forward-looking statements regarding events, performance and financial trends. Various factors could affect future results and could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Some of those factors are identified in Exhibit 99.1, and in our periodic reports filed with the Securities and Exchange Commission.
|
Item 9.01.
|
Financial Statements and Exhibits
|
|
(d)
|
Exhibits.
|
The following exhibit is filed herewith:
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press release issued by Atrinsic, Inc., dated March 31, 2011.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Atrinsic, Inc.
|
|||
|
Date: April 1, 2011
|
By:
|
/s/ Thomas Plotts
|
|
| Thomas Plotts | |||
|
Chief Financial Officer
|
|||